These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

57 related items for PubMed ID: 7741408

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.
    Funck-Brentano C, Thomas G, Jacqz-Aigrain E, Poirier JM, Simon T, Béréziat G, Jaillon P.
    J Pharmacol Exp Ther; 1992 Nov; 263(2):780-6. PubMed ID: 1432700
    [Abstract] [Full Text] [Related]

  • 3. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.
    Vandel P, Haffen E, Nezelof S, Broly F, Kantelip JP, Sechter D.
    Hum Psychopharmacol; 2004 Jul; 19(5):293-8. PubMed ID: 15252821
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K, Tybring G, Härtter S, Andersson K, Svensson JO, Widén J, Bertilsson L.
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
    Hou ZY, Chen CP, Yang WC, Lai MD, Buchert ET, Chung HM, Pickle LW, Woosley RL.
    Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
    [Abstract] [Full Text] [Related]

  • 8. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F, Meyer UA.
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lack of surface expression for the B-cell autoepitope of cytochrome P450 IID6 evidenced by flow cytometry.
    Trautwein C, Gerken G, Löhr H, Meyer zum Büschenfelde KH, Manns M.
    Z Gastroenterol; 1993 Apr; 31(4):225-30. PubMed ID: 7684170
    [Abstract] [Full Text] [Related]

  • 11. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.
    Zhou-Pan XR, Sérée E, Zhou XJ, Placidi M, Maurel P, Barra Y, Rahmani R.
    Cancer Res; 1993 Nov 01; 53(21):5121-6. PubMed ID: 8221648
    [Abstract] [Full Text] [Related]

  • 12. Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro.
    Wu D, Otton SV, Morrow P, Inaba T, Kalow W, Sellers EM.
    J Pharmacol Exp Ther; 1993 Aug 01; 266(2):715-9. PubMed ID: 8355202
    [Abstract] [Full Text] [Related]

  • 13. Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference?
    Vandel P, Haffen E, Vandel S, Bonin B, Sechter D, Bizouard P, Dalery J.
    Therapie; 2000 Aug 01; 55(3):349-53. PubMed ID: 10967711
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
    Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, Bertschy G.
    Ther Drug Monit; 2008 Aug 01; 30(4):474-82. PubMed ID: 18641553
    [Abstract] [Full Text] [Related]

  • 17. [Biotransformation of sparteine in the Cuna American Indians of Panama].
    Arias TD, Jorge L, Lee D, Guerrero de Solís N, Escobar J, Barrantes R, Inaba T.
    Rev Med Panama; 1986 Sep 01; 11(3):199-209. PubMed ID: 3468564
    [No Abstract] [Full Text] [Related]

  • 18. Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis.
    van Vugt-Lussenburg BM, Stjernschantz E, Lastdrager J, Oostenbrink C, Vermeulen NP, Commandeur JN.
    J Med Chem; 2007 Feb 08; 50(3):455-61. PubMed ID: 17266197
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota.
    Straka RJ, Hansen SR, Walker PF.
    Clin Pharmacol Ther; 1995 Jul 08; 58(1):29-34. PubMed ID: 7628180
    [Abstract] [Full Text] [Related]

  • 20. Debrisoquine and dextromethorphan phenotyping and antidepressant treatment.
    Perault MC, Bouquet S, Bertschy G, Vandel S, Chakroun R, Guibert S, Vandel B.
    Therapie; 1991 Jul 08; 46(1):1-3. PubMed ID: 2020918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.